SANF Share Price

Open 82.00 Change Price %
High 82.15 1 Day 0.30 0.37
Low 82.00 1 Week 1.00 1.23
Close 82.15 1 Month 0.50 0.61
Volume 61 1 Year 12.40 17.78
52 Week High 92.70
52 Week Low 66.80
SANF Important Levels
Resistance 2 82.29
Resistance 1 82.23
Pivot 82.10
Support 1 82.07
Support 2 82.01
BIT Italy Most Active Stocks
ISP 2.87 -1.03%
PMI 0.36 0.00%
PMI 0.36 0.00%
TIT 0.82 -1.20%
F 6.94 -2.12%
F 6.94 -2.12%
F 6.94 -2.12%
F 6.94 -2.12%
UCG 17.60 -0.85%
BNS 0.67 -2.90%
BIT Italy Top Gainers Stocks
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
NR 2.05 7.89%
NR 2.05 7.89%
NR 2.05 7.89%
VRW 1.13 6.60%
VRW 1.13 6.60%
RM 0.53 6.00%
BIT Italy Top Losers Stocks
RN 0.03 -25.00%
RN 0.03 -25.00%
ME 0.09 -10.00%
ME 0.09 -10.00%
EEMS 0.09 -10.00%
BMPS 15.08 -7.48%
ENV 3.30 -4.07%
ENV 3.30 -4.07%
ENV 3.30 -4.07%
ENV 3.30 -4.07%

Sanofi (BIT: SANF)

SANF Technical Analysis 1.5
As on 22nd Aug 2017 SANF Share Price closed @ 82.15 and we RECOMMEND Buy for LONG-TERM with Stoploss of 79.90 & Sell for SHORT-TERM with Stoploss of 83.90 we also expect STOCK to react on Following IMPORTANT LEVELS.
SANF Target for August
1st Target up-side 83.84
2nd Target up-side 85.91
3rd Target up-side 87.97
1st Target down-side 77.96
2nd Target down-side 75.89
3rd Target down-side 73.83
SANF Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website
SANF Address
54, Rue La Bo
Paris, 75008
Phone: 33 1 53 77 40 00
SANF Latest News
SALES LEADS: Spotify, Sanofi, Coors Light…   - 21st Aug 17
Sanofi shifts US$1billion media buying account to Mindshare   Marketing Interactive   - 21st Aug 17
WPP Is the Big Winner In Pharma Giant Sanofi's $1 Billion Global Review   Adweek   - 18th Aug 17
Sanofi tip ends in $465M settlement between Mylan and DOJ   FiercePharma   - 18th Aug 17
Lexicon builds case for Sanofi-partnered diabetes pill   FierceBiotech   - 15th Aug 17
Sanofi's Zika Standoff: Bad Medicine?   Seeking Alpha   - 11th Aug 17
An Also-Ran in Cancer Drugs, Sanofi Sees Chance to Close the Gap   Bloomberg   - 08th Aug 17
Sanofi raises outlook after strong second-quarter sales   Financial Times   - 31st Jul 17
Sanofi profit falls 10% as restructuring costs hit   MarketWatch   - 31st Jul 17
The Drug Maker Sanofi's New Dengue Vaccine   New York Times   - 24th Jul 17
Interactive Technical Analysis Chart Sanofi ( SANF BIT Italy )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Sanofi
SANF Business Profile
Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances with Bristol-Myers Squibb, Regeneron, Warner Chilcott, and Regulus Therapeutics Inc., as well as a strategic collaboration with UCB S.A. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.